CCA
AIMT

Catalyst Capital Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Catalyst Capital Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-174
Closed -$3K – 668
2015
Q4 		$3K Buy
+174
New +$3.22K ﹤0.01% 504

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Catalyst Capital Advisors's AIMT Position: Q1 2016 in Review

Catalyst Capital Advisors sold out of Aimmune Therapeutics (AIMT) in Q1 2016, closing a stake of 174 shares — an estimated $3K sold.

Catalyst Capital Advisors first reported a position in AIMT in Q4 2015 and held it in 1 quarter. The position peaked at $3K in Q4 2015. 69 funds tracked by Wall St. Rank hold AIMT as of Q1 2016.

  • Catalyst Capital Advisors reported no remaining Aimmune Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 174 Aimmune Therapeutics shares in Q1 2016, an estimated $3K.
  • Catalyst Capital Advisors first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 1 quarter.
  • Catalyst Capital Advisors's Aimmune Therapeutics position peaked at $3K in Q4 2015.
  • 69 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2016.

Based on Catalyst Capital Advisors's 13F filing for Q1 2016, filed 11 May 2016.